[Corrigendum] Efficacy of transarterial chemoembolization‑hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis  

Subsequently to the publication of the above paper, the authors have contacted the Editrial Office to explain that, due to an inadvertent file upload error made during the submission process, Table I contained incorrect data regarding treatment‑related adverse events in Group 1 (n=16 patients). The corrected version of Table I is shown on the next two pages, and the correct data for the Treatment‑related adverse events in Group 1 column are highlighted in bold. As a result of the inclusion of the incorrect data in Table I, the corresponding paragraph in the Results section (p. 3, the right‑hand column) also contained inaccuracies. The text starting from line 36 should have as follows: “Treatment‑related adverse events (AEs) were significantly more frequent and severe in Group 1 compared with the other groups (all P<0.001). In Group 1 (n=16), the most common adverse events included nausea and vomiting (14 patients, 87.5%), weight loss (13 patients, 81.2%), abdominal pain (12 patients, 75.0%), decreased appetite (12 patients, 75.0%), diarrhea (11 patients, 68.8%), rash (11 patients, 68.8%), fatigue (9 patients, 56.2%), hand‑foot syndrome (6 patients, 37.5%), immune‑related pneumonitis (5 patients, 31.2%), and hemorrhagic (bleeding) events (5 patients, 31.2%). Oral mucositis occurred in 7 patients (43.8%). No treatment‑related deaths were observed in any group.” Finally, the authors requested that an update be made to the corresponding author’s email address for long‑term academic correspondence. Although the originally listed email (ruibaoliu111@sina.com) remains active, Dr Ruibao Liu now uses liu_ruibao@sina.com as his primary and stable professional contact address, and the authors request that this email address should be used for all professional correspondence in the future. Note that all the other data in the manuscript, including the baseline characteristics (for example, ascites, hepatitis C status and tumor burden), laboratory values, survival outcomes and statistical conclusions remain accurate and unchanged. The authors wished to confirm that the main findings and clinical implications of the study are unaffected by the errors that were made in Table I. The authors regret that these errors went unnoticed prior to the publication of this paper, and apologize to the readership for any inconvenience caused. [Oncology Letters 30: 363, 2025; DOI: 10.3892/ol.2025.15109]